AMED icon

Amedisys

94.90 USD
+0.18
0.19%
At close Apr 30, 4:00 PM EDT
After hours
94.90
+0.00
0.00%
1 day
0.19%
5 days
0.96%
1 month
2.45%
3 months
2.69%
6 months
-0.37%
Year to date
4.40%
1 year
3.10%
5 years
-48.47%
10 years
241.24%
 

About: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Employees: 19,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 80

22% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 45

3% more funds holding

Funds holding: 276 [Q3] → 284 (+8) [Q4]

2.37% more ownership

Funds ownership: 86.51% [Q3] → 88.88% (+2.37%) [Q4]

3% less capital invested

Capital invested by funds: $2.73B [Q3] → $2.64B (-$91.2M) [Q4]

17% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 10 (-2) [Q4]

80% less call options, than puts

Call options by funds: $72.1M | Put options by funds: $360M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$100
5%
upside
Avg. target
$101
6%
upside
High target
$101
6%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
RBC Capital
Ben Hendrix
35% 1-year accuracy
25 / 71 met price target
5%upside
$100
Outperform
Reiterated
16 Apr 2025
Stephens & Co.
Scott Fidel
45% 1-year accuracy
18 / 40 met price target
6%upside
$101
Equal-Weight
Reiterated
4 Mar 2025
Stephens & Co.
Raj Kumar
57% 1-year accuracy
4 / 7 met price target
6%upside
$101
Equal-Weight
Reiterated
12 Feb 2025

Financial journalist opinion

Based on 5 articles about AMED published over the past 30 days

Positive
Zacks Investment Research
6 days ago
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
Positive
Zacks Investment Research
1 week ago
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
1 week ago
Amedisys (AMED) Tops Q1 Earnings Estimates
Amedisys (AMED) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.03 per share a year ago.
Amedisys (AMED) Tops Q1 Earnings Estimates
Neutral
GlobeNewsWire
1 week ago
Amedisys Reports First Quarter 2025 Financial Results
BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025.
Amedisys Reports First Quarter 2025 Financial Results
Neutral
Zacks Investment Research
2 weeks ago
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
1 month ago
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Retain AMED Stock in Your Portfolio Now
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Here's Why You Should Retain AMED Stock in Your Portfolio Now
Neutral
Zacks Investment Research
1 month ago
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
Neutral
Zacks Investment Research
2 months ago
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
2 months ago
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates
Amedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago.
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates
Charts implemented using Lightweight Charts™